Observational study of fibrinogen for diagnosis of GCA At a cutoff of 4.7, roughly similar diagnostic performance as compared to ESR/CRP Kind of neat, but does not appear to have additive benefit #ACR25 @RheumNow Abstr#0750 https://t.co/xy2qn4jHXP

• https://x.com/EBRheum/status/1982481345915040253/photo/1

ILD found in 30% of Sjögren’s pts w/ HRCT. A new nomogram-based tool (AUC 0.8) predicts ILD risk using age, ESR, C3, hypergammaglobulinemia & anti-La/SSB. Goal: guide HRCT referrals & catch ILD earlier. @RheumNow #ACR25 Abstract #0510 https://t.co/FvAprq8eol

• https://x.com/JihaRheum/status/1982478326150447224/photo/1

2-Year data from SELECT-GCA Phase 3 UPA in GCA Re-randomization & 52 weeks extension UPA 15mg vs. PBO -Risk of flare 90% lower -Complete remission 70% vs 20% -Cumulative GC 1g difference -No new safety signal The quick relapse after stopping UPA indicates we are really looking https://t.co/c1khywnPNv

• https://x.com/AurelieRheumo/status/1982478272697909405/photo/1
• https://x.com/AurelieRheumo/status/1982478272697909405/photo/1

Immune-Mediated Necrotizing Myopathy @EleniTiniakou #ACR25 *Younger pts tend to have a more aggressive disease *IVIG and RTX can be considered first-line rx for anti-HMGCR and anti-SRP+, respectively *CYC and plasmapheresis may be options in cases of aggressive disease https://t.co/zWDX79gqlf

• https://x.com/RheumQuarterly/status/1982461272500097265/photo/1

Abstract 0806 Compared to belimumab, Anifrolumab associated with: ↑ infection risk b (HR 1.40, 95% CI 1.05–1.88) ↑ herpes zoster (HR 3.94) & COVID-19 (HR 1.66) No diff in mortality or hospital use 📈 3-yr infection: 38.3% vs 21.3% @RheumNow #ACR25

Real world effectiveness of voclosporin for SLE Reduction in UPCR from 2.1 at b/l to 0.9 at 6 months, no improvement in eGFR; as expected based on trials Wonder about market share of BEL vs voclo vs ANI - anyone seen pubs on this? #ACR25 @RheumNow Abstr#0661 https://t.co/l7i7IWhLSe

• https://x.com/EBRheum/status/1982478074810662970/photo/1

#ACR25 Abstr#775 Previous study showed plasma tRNA-derived RNA (tDR-1), produced by bacteria from the phylum Proteobacteria, was assoc. with lower RA activity. In 60 At-Risk CCP3+ people, Plasma tDR-1 improved prediction of RA. Need validation & adoption in practice @RheumNow https://t.co/XBmtohBEHc

• https://x.com/Yuz6Yusof/status/1982477761924272617/photo/1

From the FOREMOST study factors predicting progression from oligo to polyarticular PsA: Female sex, enthesitis and dactylitis found to increase the risk of progression. Among patients in FOREMOST receiving PBO, prior csDMARD use was protective. Abstract#0576 @RheumNow #ACR25 https://t.co/CFMhAFgFBa

• https://x.com/synovialjoints/status/1982477323505906048/photo/1

Accdg to this retro analysis of their prospective cohort study from Toronto, 47 pts (10%) had D2M axSpA of whom 14 had tx-refractory dse. D2M pts - longer symptom duration; ⬆️ASDAS, BASDAI, BASMI, BASFI & ⬆️CRP 💡Consider non-dse factors in D2M pts #ACR25 @RheumNow Abs0547 https://t.co/MUUyyELbw8

• https://x.com/RHEUMarampa/status/1982477322969354626/photo/1

#0191 We found that in a large South London RA cohort, use of advanced therapy in moderate disease (DAS28 3.2-5.1) generally followed NICE guidance. Gaps often reflected telehealth limiting DAS assessment and patient hesitancy. Self-assessment tools may help. @RheumNow #ACR25 https://t.co/UMGtkfABHn

• https://x.com/DrMiniDey/status/1982477322843472089/photo/1

Real-world T2T strategy from MONITOR-PsA cohort: 🎯 At 48 weeks - 33.6% (49/146) of pts achieved PASDAS 'moderate' response & 37% (54/146) achieved a 'good' response This was close to the T2T outcomes of the TICOPA trial Adapt a T2T approach in PsA tx #ACR25 @RheumNow Abs0572 https://t.co/FPiFIiO8Oe

• https://x.com/RHEUMarampa/status/1982477321555640449/photo/1
• https://x.com/RHEUMarampa/status/1982477321555640449/photo/1

Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA and RF disappeared. Results maybe not as positive as we might have anticipated? @RheumNow #ACR25 Abstr#471 https://t.co/TaEVWiWsNm

• https://x.com/RichardPAConway/status/1982477067988992375/photo/1

SELECT-GCA (upadacitinib in GCA for 52w) we hoped it might have ongoing effect post-cessation Do we need to continue upa? Extension data (second year) flare survival curves are clear: continuing upa far outperforms placebo It seems >2y toci/upa for GCA #ACR25 ABST0776 @RheumNow https://t.co/uJA3uQyWxb

• https://x.com/drdavidliew/status/1982476822744121513/photo/1

#0776 In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO, cutting flare risk by 90% and reducing steroid exposure by ~1g. No new safety signals in older adults (mean 71yrs). @RheumNow #ACR25 https://t.co/KC9sm3ic3q

• https://x.com/DrMiniDey/status/1982476564739620938/photo/1